Total Payments
$646,664
2024 Payments
$113,165
Companies
42
Transactions
1,553
Medicare Patients
880
Medicare Billing
$131,307
Payment Breakdown by Category
Other$565,000 (87.4%)
Travel$38,747 (6.0%)
Food & Beverage$34,581 (5.3%)
Consulting$8,006 (1.2%)
Education$329.75 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $545,315 | 249 | 84.3% |
| Travel and Lodging | $38,747 | 232 | 6.0% |
| Food and Beverage | $34,581 | 1,043 | 5.3% |
| Honoraria | $19,685 | 9 | 3.0% |
| Consulting Fee | $8,006 | 6 | 1.2% |
| Education | $329.75 | 14 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $253,990 | 479 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $127,551 | 207 | $0 (2020) |
| Lilly USA, LLC | $95,096 | 206 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $74,844 | 154 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $68,042 | 199 | $0 (2024) |
| Orexigen Therapeutics, Inc. | $11,157 | 25 | $0 (2018) |
| Currax Pharmaceuticals LLC | $10,421 | 21 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $817.72 | 27 | $0 (2023) |
| EISAI INC. | $604.23 | 48 | $0 (2019) |
| KVK-Tech, Inc. | $524.87 | 20 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $113,165 | 198 | Lilly USA, LLC ($55,383) |
| 2023 | $68,434 | 110 | Novo Nordisk Inc ($46,553) |
| 2022 | $96,620 | 157 | Novo Nordisk Inc ($74,445) |
| 2021 | $42,513 | 109 | Novo Nordisk Inc ($17,141) |
| 2020 | $44,356 | 103 | AstraZeneca Pharmaceuticals LP ($14,390) |
| 2019 | $61,401 | 266 | Novo Nordisk Inc ($26,648) |
| 2018 | $46,702 | 222 | Novo Nordisk Inc ($14,297) |
| 2017 | $173,474 | 388 | Janssen Pharmaceuticals, Inc ($99,697) |
All Payment Transactions
1,553 individual payment records from CMS Open Payments — Page 1 of 63
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Currax Pharmaceuticals LLC | CONTRAVE (Drug) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: Obesity | ||||||
| 12/12/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $5.52 | General |
| Category: Obesity | ||||||
| 12/05/2024 | Radius Health, Inc. | — | Food and Beverage | In-kind items and services | $27.35 | General |
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $10.61 | General |
| Category: DIABETES | ||||||
| 11/22/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Diabetes | ||||||
| 11/21/2024 | Currax Pharmaceuticals LLC | CONTRAVE (Drug) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: Obesity | ||||||
| 11/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SYNJARDY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $10.77 | General |
| Category: DIABETES | ||||||
| 11/04/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $87.36 | General |
| Category: Obesity | ||||||
| 10/31/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Diabetes | ||||||
| 10/31/2024 | Currax Pharmaceuticals LLC | CONTRAVE (Drug) | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: Obesity | ||||||
| 10/24/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $97.55 | General |
| 10/17/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,437.50 | General |
| Category: Obesity | ||||||
| 10/17/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $101.92 | General |
| Category: Obesity | ||||||
| 10/17/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $28.14 | General |
| Category: Obesity | ||||||
| 10/17/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $10.08 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,656.25 | General |
| Category: Obesity | ||||||
| 10/16/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $125.96 | General |
| Category: Obesity | ||||||
| 10/16/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $42.92 | General |
| Category: Obesity | ||||||
| 10/16/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $15.94 | General |
| Category: Obesity | ||||||
| 10/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $10.89 | General |
| Category: DIABETES | ||||||
| 09/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $28.28 | General |
| Category: Diabetes | ||||||
| 09/19/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: Diabetes | ||||||
| 09/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: DIABETES | ||||||
| 09/17/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,843.75 | General |
| Category: Obesity | ||||||
| 09/17/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,531.25 | General |
| Category: Obesity | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 254 | 388 | $143,200 | $39,699 |
| 2022 | 3 | 192 | 311 | $113,601 | $31,616 |
| 2021 | 3 | 198 | 292 | $106,700 | $30,979 |
| 2020 | 3 | 236 | 355 | $83,649 | $29,013 |
Total Patients
880
Total Services
1,346
Medicare Billing
$131,307
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 183 | 317 | $111,045 | $31,355 | 28.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 71 | 71 | $32,154 | $8,344 | 26.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 121 | 218 | $76,412 | $20,743 | 27.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 45 | 45 | $20,365 | $6,196 | 30.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 26 | 48 | $16,823 | $4,677 | 27.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 108 | 181 | $63,155 | $18,280 | 28.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 48 | 48 | $21,614 | $6,853 | 31.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 42 | 63 | $21,931 | $5,846 | 26.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 83 | 148 | $15,392 | $11,677 | 75.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 103 | 157 | $46,197 | $11,251 | 24.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 50 | 50 | $22,060 | $6,085 | 27.6% |
About Raymond Plodkowski
Raymond Plodkowski is a Endocrinology, Diabetes & Metabolism healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104831247.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Raymond Plodkowski has received a total of $646,664 in payments from pharmaceutical and medical device companies, with $113,165 received in 2024. These payments were reported across 1,553 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($545,315).
As a Medicare-enrolled provider, Plodkowski has provided services to 880 Medicare beneficiaries, totaling 1,346 services with total Medicare billing of $131,307. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location San Diego, CA
- Active Since 07/29/2006
- Last Updated 09/20/2012
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1104831247
Products in Payments
- INVOKANA (Drug) $127,668
- JARDIANCE (Drug) $124,098
- Saxenda (Drug) $120,752
- Wegovy (Drug) $101,016
- FARXIGA (Drug) $58,236
- ZEPBOUND (Drug) $37,557
- Rybelsus (Drug) $25,983
- CONTRAVE (Drug) $21,804
- BYDUREON (Drug) $9,708
- Ozempic (Drug) $1,958
- Belviq (Drug) $604.23
- TRADJENTA (Drug) $459.40
- SOLIQUA (Drug) $455.82
- JANUVIA (Drug) $407.30
- MOUNJARO (Drug) $375.49
- TRULICITY (Drug) $360.86
- Korlym (Drug) $337.31
- TOUJEO (Drug) $282.00
- Victoza (Drug) $275.72
- Tresiba (Drug) $238.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in San Diego
Dr. Juan Frias, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $3.6M
Endocrinology, Diabetes & Metabolism $3.6M
Dr. Ken Fujioka, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $901,352
Endocrinology, Diabetes & Metabolism $901,352
Dr. Jeremy Pettus
Endocrinology, Diabetes & Metabolism — Payments: $809,314
Endocrinology, Diabetes & Metabolism $809,314
Suvesh Chandiok, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $192,681
Endocrinology, Diabetes & Metabolism $192,681
Dr. Chris Guerin, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $78,706
Endocrinology, Diabetes & Metabolism $78,706
Dr. Sunder Mudaliar, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $68,318
Endocrinology, Diabetes & Metabolism $68,318